Literature DB >> 21403953

Optimization of immunoaffinity enrichment and detection: toward a comprehensive characterization of the phosphotyrosine proteome of K562 cells by liquid chromatography-mass spectrometry.

Konstantin A Artemenko1, Sara Bergström Lind, Lioudmila Elfineh, Corina Mayrhofer, Roman A Zubarev, Jonas Bergquist, Ulf Pettersson.   

Abstract

Phosphorylation of protein tyrosine residues regulates many cell functions and has also been proved to be involved in oncogenesis. Thus, the identification of the phosphotyrosine (pTyr) proteome of cells is a very important task. Since tyrosine phosphorylation represents only around 1% of the total human phosphoproteome, the study of pTyr proteins is rather challenging. Here we report the optimization study of the phosphotyrosine proteome using K562 cells as a model system. A substantial segment of the phosphotyrosine proteome of K562 cells was characterized by immunoaffinity enrichment with 4G10 and PYKD1 antibodies followed by LC-MS/MS analysis. 480 non-redundant pTyr peptides corresponding to 342 pTyr proteins were found. 141 pTyr peptides were not described elsewhere. The mass spectrometry approach involving high-resolving FTMS analysis of precursor ions and subsequent detection of CID fragments in a linear ion trap was considered as optimal. For detection of low abundant pTyr peptides pooling of individual immunoaffinity enrichments for one LC-MS/MS analysis was crucial. The enrichment properties of the monoclonal PYKD1 antibody were presented for the first time, also in comparison to the 4G10 antibody. PYKD1 was found to be more effective for protein enrichment (1.2 and 5% efficiency at peptide and protein level correspondingly), while 4G10 showed better results when peptide enrichment was performed (15% efficiency versus 3.6% at protein level). Substantially different subsets of the phosphoproteome were enriched by these antibodies. This finding together with previous studies demonstrates that comprehensive pTyr proteome characterization by immunoprecipitation requires multiple antibodies to be used for the affinity enrichment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403953     DOI: 10.1039/c0an00649a

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  6 in total

Review 1.  Proteins and Proteoforms: New Separation Challenges.

Authors:  Fred E Regnier; JinHee Kim
Journal:  Anal Chem       Date:  2017-12-18       Impact factor: 6.986

2.  A conserved rod domain phosphotyrosine that is targeted by the phosphatase PTP1B promotes keratin 8 protein insolubility and filament organization.

Authors:  Natasha T Snider; Haewon Park; M Bishr Omary
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

3.  Hormone replacement therapy improves contractile function and myonuclear organization of single muscle fibres from postmenopausal monozygotic female twin pairs.

Authors:  Rizwan Qaisar; Guillaume Renaud; Yvette Hedstrom; Eija Pöllänen; Paula Ronkainen; Jaakko Kaprio; Markku Alen; Sarianna Sipilä; Konstantin Artemenko; Jonas Bergquist; Vuokko Kovanen; Lars Larsson
Journal:  J Physiol       Date:  2013-03-04       Impact factor: 5.182

4.  GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL).

Authors:  Morten F Gjerstorff; Heike I Rösner; Christina B Pedersen; Katrine B V Greve; Steffen Schmidt; Katherine L Wilson; Jan Mollenhauer; Hüseyin Besir; Flemming M Poulsen; Niels Erik Møllegaard; Henrik J Ditzel
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

5.  Tyrosine phosphorylation profiling via in situ proximity ligation assay.

Authors:  Lioudmila Elfineh; Christina Classon; Anna Asplund; Ulf Pettersson; Masood Kamali-Moghaddam; Sara Bergström Lind
Journal:  BMC Cancer       Date:  2014-06-13       Impact factor: 4.430

Review 6.  Proteomic discovery of host kinase signaling in bacterial infections.

Authors:  Erik Richter; Jörg Mostertz; Falko Hochgräfe
Journal:  Proteomics Clin Appl       Date:  2016-09-09       Impact factor: 3.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.